A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days ...

Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company currently valued at $32.66 million, recently executed... Passage Bio ...

The U.S. IPO market seems to be cooling off this week, with no major listing planned. This week, Advanced Biomed ( ADVB) is ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Bluebird Bio (NASDAQ:BLUE) stock in focus as company intends to go private in M&A deal with Carlyle Group (CG) & SK Capital. Read more here.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem ...

Shares of NASDAQ BBNX opened at $20.57 on Thursday. Beta Bionics has a 52-week low of $20.57 and a 52-week high of $24.50. In related news, insider Mike Mensinger purchased 33,350 shares of Beta ...

VSTM stock opened at $5.68 on Friday. The stock has a market capitalization of $252.80 million, a P/E ratio of -1.78 and a beta of 0.28. The company has a current ratio of 3.23, a quick ratio of 3 ...

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year.

The shift happens with the issuance of shares of stocks in a trading exchange. The people who purchase the shares at the IPO price can gain by selling those when they increase in value after listing.

2-Year U.S. Treasury Note Continuous Contract $102.844-0.043-0.04% 5-Year U.S. Treasury Note Continuous Contract $106.742-0.078-0.07% 10-Year U.S. Treasury Note Continuous Contract $109.609-0.078 ...

Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight ...